Lipella Pharmaceuticals receives FDA approval for a Type C meeting to discuss LP-10's Phase-2b trial design for hemorrhagic cystitis.
Lipella Pharmaceuticals (LIPO) received approval for a Type C meeting with the FDA to discuss its proposed Phase-2b clinical trial design for LP-10 as a potential treatment for moderate to severe hemorrhagic cystitis. The meeting is set for May 21, 2024, to reach agreement on the trial design. Lipella's CMO, Michael Chancellor, expects this meeting to significantly improve LP-10's regulatory prospects.
April 03, 2024
3 Articles